Identification of small molecules that support human leukemia stem cell activity ex vivo

Nature Methods

Volumn 11, Issue 4, 2014, Pages 436-442

  Pabst, Caroline ^a,c   Krosl, Jana ^a,c   Fares, Iman ^a,c   Boucher, Geneviève ^a,c   Ruel, Réjean ^a,c   Marinier, Anne ^a,b,c   Lemieux, Sébastien ^a,b,c   Hébert, Josée ^a,b,c   Sauvageau, Guy ^a,b,c  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; INDOLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CONTROLLED STUDY; EX VIVO STUDY; GENETIC VARIABILITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMIC STEM CELL; MALE; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMALL MOLECULE; STEM CELL;

ADENINE; CELL CULTURE TECHNIQUES; CULTURE MEDIA, SERUM-FREE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; LEUKEMIA; LEUKEMIA, MYELOID, ACUTE; MOLECULAR STRUCTURE; NEOPLASTIC STEM CELLS; PYRIMIDINES;

EID: 84897954369     PISSN: 15487091     EISSN: 15487105     Source Type: Journal    
DOI: 10.1038/nmeth.2847     Document Type: Article

References (34)

1. Burnett, A., Wetzler, M. & Lowenberg, B. Therapeutic advances in acute myeloid leukemia. Clin. Oncol. 29, 487 -494 (2011
2. Dick, J. & Lapidot, T. Biology of normal and acute myeloid leukemia stem cells. Int. J. Hematol. 82, 389-396 (2005
3. Hope, K., Jin, L. & Dick, J. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 5, 738-743 (2004
4. Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648 (1994
5. Pearce, D. et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: Implications for our understanding of the heterogeneity of AML. Blood 107, 1166-1173 (2006
6. Woiterski, J. et al. Engraftment of low numbers of pediatric acute lymphoid a nd myeloid leukemias into NOD/SCID/IL2Rcnull mice reflects individual leukemogenecity and highly correlates with clinical outcome. Int. J. Cancer 133, 1547- 1556 (2013
7. Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17, 1086 -1093 (2011
8. Gentles, A., Plevritis, S., Majeti, R. & Alizadeh, A. Association of a leukemi c stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. J. Am. Med. Assoc. 304, 2706-2715 (2010
9. Csaszar, E. et al. Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling. Cell Stem Cell 10, 218 -229 (2012
10. Boitano, A.E. et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329, 1345 -1348 (2010
11. Mayani, H., Flores-Figueroa, E. & Chavez-Gonzalez, A. In vitro biology of human myeloid leukemia. Leuk. Res. 33, 624-637 (2009
12. Barabe, F., Kennedy, J.A., Hope, K.J. & Dick, J.E. Modeling the initiation and progression of human acute leukemia in mice. Science 316, 600-604 (2007
13. Heuser, M. et al. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood 110, 1639-1647 (2007
14. Choi, J.-S., Braymer, J., Nanga, R., Ramamoorthy, A. & Lim, M. Design of small molecules that target metal-A{beta} species and regulate metal-induced A{beta} aggregation and neurotoxicity. Proc. Natl. Acad. Sci. USA 107, 21990-21995 (2010
15. Borowiak, M. et al. Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell S tem Cell 4, 348-358 (2009
16. Feng, B., Ng, J.-H., Heng, J.-C.D. & Ng, H.-H. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 4, 301-312 (2009
17. Bone, H., Nelson, A., Goldring, C., Tosh, D. & Welham, M. A novel chemically directed route for the generation of definitive endoderm from human embryonic stem cells based on inhibition of GSK-3. J. Cell Sci. 124, 1992-2000 (2011
18. Sauvageau, G. Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells. PCT/CA2013/050052, WO/2013/110198 (2013
19. Denison, M. & Nagy, S. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol. 43, 309-334 (2003
20. Henry, E. et al. Flavone antagonists bind competitively with 2,3,7, 8-tetrachlorodibenzo-p-dioxin (TCDD) to the aryl hydrocarbon receptor but inhibit nuclear uptake and transformation. Mol. Pharmacol. 55, 716-725 (1999
21. Bouchez, L.C. et al. Small-molecule regulators of human stem cell self-renewal. ChemBioChem 12, 854- 857 (2011
22. Knockaert, M. et al. Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. Oncogene 23, 4400-4412 (2004
23. Opitz, C.A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197 -203 (2011
24. Swanson, H. DNA binding and protein interaction s of the AHR/ARNT heterodimer that facilitate gene activation. Chem. Biol. Interact. 141, 63-76 (2002
25. Denison, M., Soshilov, A., He, G., DeGroot, D. & Zhao, B. Exactly the same but diffe rent: Promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. Toxicological sciences 124, 1- 22 (2011
26. Krger, T., Long, M. & Bonefeld-Jr gensen, E. Plastic components affect the activation of the aryl hydrocarbon and the androgen receptor. Toxicology 246, 112-123 (2008
27. Bhakta, K. et al. Regulation of cytochrome P4501A1 expressi on by hyperoxia in human lung cell lines: Implications for hyperoxic lung injury. Toxicol. Appl. Pharmacol. 233, 169-178 (2008
28. Magnusson, M. et al. Expansion on stromal cells preserves the undifferentia ted state of human hematopoietic stem cells despite compromised reconstitution ability. PLoS ONE 8, e53912 (2013
29. Taussig, D. et al. Leukemia-initiating cells from some acute myeloid leukemia patients w ith mutated nucleophosmin reside in the CD34() fraction. Blood 115, 1976-1984 (2010
30. U.S. Department of Health and Human Services, National Toxicology Program, Report on Carcinogens, Twelfth Edition, p. 353 ff. and 396 (2011
31. Prudhomme, G.J. et al. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS ONE 5, e13831 (2010
32. .Xiao, Z., Hao, Y., Liu, B. & Qian, L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk. Lymphoma 43, 1763-1768 (2002
33. Simon, C. et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 26, 651 -656 (2012
34. Hu, Y. & Smyth, G.K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347, 70-78 (2009